Compounding Regulation Bill In Senate May Actually Encourage More Activity, Groups Argue
This article was originally published in The Pink Sheet Daily
Executive Summary
Some stakeholders worry that increased oversight of compounding may incentivize an expansion of the sector over traditional FDA-controlled manufacturing, but a compounding trade group thinks some provisions restrict prescriber ability to customize medications.
You may also be interested in...
Compounding: How Does FDA Expand Oversight Without Legislation?
After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.